Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty
Service de Cardiologie, Höpital Bichat Paris, France
revised 15 October 1996; accepted 16 October 1996.
Correspondence: A. Boccara, MD, Service de Cardiologie, Höpital Bichat, 46 Rue Henri Huchard, 75018, Paris, France
Abstract
AIMS: Prospectively to compare success rate and complications in percutaneous transluminal coronary angioplasty using two doses of heparin.
METHODS AND RESULTS: Four hundred patients undergoing coronary angioplasty were randomly assigned to receive 15 000 IU (group A) or 100 IU. kg –1 (group B) of heparin. The angioplasty success rate was 95% in both groups. Stents were placed in 28·5% and 26·5% of patients in groups A and B, respectively (P=0·73). The primary endpoint (freedom from death, myocardial infarction, unplanned revascularization or bailout stenting) occurred in 91% vs 95% of patients in groups A and B, respectively (odds ratio: 1·88, 95% CI: 0·80—4·50, P=0·12). Haemoglobin loss was 0·36 ± 1 and 0·27 ± 0·9 g. dl –1 in groups A and B, respectively (P=0·37). The time to sheath removal (735 ± 265 vs 558 ± 246 min) and the time to transfer to a stepdown unit (12·7 ± 4·5 vs 9·8 ± 4·2 h) were longer in groups A (P=0·0001 for both comparisons).
CONCLUSION: A weight-adjusted low dose of intravenous heparin is at least as safe as a fixed high dose for coronary angioplasty. It allows earlier sheath removal and discharge to a stepdown unit.
Key Words: Abrupt closure • angioplasty • heparin • lenght of stay
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Workman, H. J. Cloft, F. C. Tong, J. E. Dion, M. E. Jensen, W. F. Marx, and D. F. Kallmes Thrombus Formation at the Neck of Cerebral Aneurysms during Treatment with Guglielmi Detachable Coils AJNR Am. J. Neuroradiol., October 1, 2002; 23(9): 1568 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, and E. J. Topol Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention : Aggregate Results From 6 Randomized, Controlled Trials Circulation, February 20, 2001; 103(7): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]
|
|
|
|
|
|
B. Jorgensen, S. Simonsen, K. Endresen, K. Forfang, K. Vatne, J. Hansen, J. Webb, C. Buller, G. Goulet, J. Erikssen, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) J. Am. Coll. Cardiol., March 1, 2000; 35(3): 592 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Wilson, L. Saward, P. Zahradka, and P. Kee Cheung Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model Cardiovasc Res, June 1, 1999; 42(3): 761 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A GARACHEMANI and B MEIER Heparin for coronary angioplasty: high dose, low dose, or no dose? Heart, July 1, 1998; 80(1): 3 - 4. [Full Text]
|
|